---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030353"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:27:20.221399+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt invests $1.5M in Evofem via convertible note and warrant as part of merger extension

## Summary
- Aditxt purchased a $2,307,692 senior subordinated convertible note of Evofem and a warrant for 149,850,150 shares of Evofem common stock for $1,500,000.
- $750,000 of the purchase price was funded on April 8, 2025; remaining $750,000 due by April 16, 2025 under a waiver agreement.
- Note bears 8% interest (12% on default), matures April 8, 2028, convertible at $0.0154 per share; warrant exercise price also $0.0154, five-year term.
- Evofem waived its termination right under the merger agreement until April 16, 2025; end date extended to September 30, 2025.
- Transaction is part of Amendment No. 5 to the Amended and Restated Merger Agreement between Aditxt, Adifem, and Evofem.

## SEC filing metadata
- accession: 0001213900-25-030353
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025030353/0001213900-25-030353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025030353/ea0237743-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030353
- JSON: https://secwatch.observer/filing/0001213900-25-030353.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.